Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings data on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01), FiscalAI reports. The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $2.50 million.

Citius Oncology Stock Up 10.0%

NASDAQ CTOR traded up $0.08 during trading hours on Friday, hitting $0.91. The company had a trading volume of 257,395 shares, compared to its average volume of 122,617. Citius Oncology has a fifty-two week low of $0.49 and a fifty-two week high of $2.25. The company has a quick ratio of 0.12, a current ratio of 0.50 and a debt-to-equity ratio of 0.11. The firm’s 50 day moving average is $0.68 and its 200 day moving average is $0.82.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC purchased a new stake in shares of Citius Oncology in the third quarter worth about $15,582,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Citius Oncology during the 4th quarter valued at about $104,000. Geode Capital Management LLC lifted its position in Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after acquiring an additional 52,875 shares in the last quarter. Jane Street Group LLC acquired a new position in Citius Oncology during the 2nd quarter worth approximately $465,000. Finally, Bank of America Corp DE boosted its holdings in Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares during the period. Institutional investors and hedge funds own 70.52% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Citius Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.